MDSpire - Takeaway
From the Journals
Feature

EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials

An overview of key visual and anatomic findings with EYP-1901 from the DAVIO 2 and VERONA clinical trials, presented at Macula Society 2026

  • March 24, 2026

  • 6 min

Share

  • 1

    EYP-1901 offers sustained release for AMD and DME treatment.

  • 2

    Anti-VEGF therapies show limitations in long-term vision preservation.

  • 3

    The DAVIO 2 trial demonstrated EYP-1901's effectiveness comparable to aflibercept.

  • 4

    Multi-mechanism action is crucial for improved outcomes.

  • 5

    Ongoing pivotal trials include LUGANO and LUCIA scheduled for completion by 2026.

Original Source(s)

EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials

  • March 24, 2026

Related Content

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Could NPDR Be Treated Orally?

Phase 1b results for danegaptide indicate promising safety profile in patients with non-proliferative diabetic retinopathy and macular edema

  • March 24, 2026

  • 5 min
Why Glaucoma Prevalence Is Rising

... and what the eye care community must do next